Monopar Therapeutics — Director's Dealing 2025

Mar 8, 2025

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Monopar Therapeutics (MNPR)
CIK: 0001645469
Period of Report: 2025-03-04

Reporting Person: Robinson Chandler (Director, Chief Executive Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2025-03-04	Common Stock	M	6002	—	Acquired	64850	Direct
2025-03-04	Common Stock	F	1759	$31.70	Disposed	63091	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2025-03-04	Stock Options	$31.70	A	85759	Acquired	2035-03-04	Common Stock (85759)	Direct
2025-03-04	Restricted Stock Units	$0	A	79899	Acquired		Common Stock (79899)	Direct
2025-03-04	Restricted Stock Units	$	M	6002	Disposed		Common Stock (6002)	Direct

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	855589	Indirect

Footnotes

F1: Represents shares acquired on vesting and settlement of restricted stock units.

F2: Represents shares withheld by the issuer to pay for the applicable withholding tax due upon vesting of restricted stock units.

F3: 6,647 options vested on the grant date. Remainder of options vest 6/48ths on June 30, 2025, and 1/48th per month thereafter.

F4: 6,002 restricted stock units vested on the grant date. Remainder of restricted stock units vest 6/48ths on June 30, 2025, and 3/48ths per quarter thereafter.

F5: As a manager of Tactic Pharma LLC, Dr. Robinson may be deemed to share voting and dispositive power over these 855,589 shares. Dr. Robinson disclaims beneficial ownership of the 855,589 shares held by Tactic Pharma LLC, except to the extent of his pecuniary interest therein.

F6: Represents vesting of 6,002 restricted stock units on the grant date. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement.